Amedisys Inc (AMED): Price and Financial Metrics


Amedisys Inc (AMED): $139.65

-5.10 (-3.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AMED POWR Grades


  • Quality is the dimension where AMED ranks best; there it ranks ahead of 96.14% of US stocks.
  • The strongest trend for AMED is in Sentiment, which has been heading down over the past 52 weeks.
  • AMED ranks lowest in Momentum; there it ranks in the 14th percentile.

AMED Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for AMED is 2.44 -- better than 79.71% of US stocks.
  • With a year-over-year growth in debt of 35.38%, Amedisys Inc's debt growth rate surpasses 82.24% of about US stocks.
  • The volatility of Amedisys Inc's share price is greater than that of 83.12% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to AMED, based on their financial statements, market capitalization, and price volatility, are FHB, FSI, WD, BOH, and TTEC.
  • AMED's SEC filings can be seen here. And to visit Amedisys Inc's official web site, go to www.amedisys.com.

AMED Valuation Summary

  • AMED's price/earnings ratio is 24.2; this is 33.7% lower than that of the median Healthcare stock.
  • Over the past 243 months, AMED's price/earnings ratio has gone up 20.4.
  • Over the past 243 months, AMED's price/sales ratio has gone up 2.4.

Below are key valuation metrics over time for AMED.

Stock Date P/S P/B P/E EV/EBIT
AMED 2021-08-31 2.7 6.8 24.2 20.0
AMED 2021-08-30 2.6 6.6 23.3 19.2
AMED 2021-08-27 2.6 6.6 23.4 19.4
AMED 2021-08-26 2.6 6.6 23.2 19.2
AMED 2021-08-25 2.7 6.7 23.6 19.5
AMED 2021-08-24 2.7 6.8 24.1 19.9

AMED Growth Metrics

  • Its 5 year price growth rate is now at 310.76%.
  • The 2 year revenue growth rate now stands at 26.72%.
  • Its year over year net cashflow from operations growth rate is now at 79.24%.
Over the past 33 months, AMED's revenue has gone up $542,922,000.

The table below shows AMED's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 2,205.5 249.639 220.176
2021-06-30 2,196.085 270.955 247.151
2021-03-31 2,116.978 336.919 201.676
2020-12-31 2,071.519 288.952 183.608
2020-09-30 2,021.492 298.26 166.112
2020-06-30 1,972.053 262.632 128.263

AMED's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AMED has a Quality Grade of A, ranking ahead of 99.52% of graded US stocks.
  • AMED's asset turnover comes in at 1.321 -- ranking 11th of 81 Healthcare stocks.
  • RDNT, CHE, and VCYT are the stocks whose asset turnover ratios are most correlated with AMED.

The table below shows AMED's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 1.321 0.446 0.742
2021-06-30 1.385 0.449 0.838
2021-03-31 1.325 0.435 0.601
2020-12-31 1.325 0.428 0.465
2020-09-30 1.359 0.419 0.395
2020-06-30 1.419 0.409 0.355

AMED Price Target

For more insight on analysts targets of AMED, see our AMED price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $240.92 Average Broker Recommendation 1.62 (Moderate Buy)

AMED Stock Price Chart Interactive Chart >

Price chart for AMED

AMED Price/Volume Stats

Current price $139.65 52-week high $325.12
Prev. close $144.75 52-week low $137.82
Day low $138.56 Volume 471,100
Day high $146.08 Avg. volume 284,716
50-day MA $162.40 Dividend yield N/A
200-day MA $224.72 Market Cap 4.55B

Amedisys Inc (AMED) Company Bio


Amedisys provides home health and hospice care services. It operates through two segments, Home Health and Hospice. The company was founded in 1982 and is based in Baton Rouge, Louisiana.


AMED Latest News Stream


Event/Time News Detail
Loading, please wait...

AMED Latest Social Stream


Loading social stream, please wait...

View Full AMED Social Stream

Latest AMED News From Around the Web

Below are the latest news stories about Amedisys Inc that investors may wish to consider to help them evaluate AMED as an investment opportunity.

New Strong Sell Stocks for November 19th

AMED, CSII, DVA, GFF, and LTRX have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2021.

Yahoo | November 19, 2021

Amedisys to Present at the Stephens Annual Investment Conference

BATON ROUGE, La., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high acuity care services, today announced that Paul B. Kusserow, Chairman and Chief Executive Officer, Chris Gerard, President and Chief Operating Officer and Scott Ginn, Executive Vice President and Chief Financial Officer will present at the Stephens Annual Investment Conference on December 3rd at 10:00 am Eastern. To access a live webcast of the Ame

Yahoo | November 19, 2021

Here's Why I Think Amedisys (NASDAQ:AMED) Might Deserve Your Attention Today

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...

Yahoo | November 18, 2021

Penn State Health Partners with Highmark Health and Contessa to Launch Home Recovery Care, a new At-Home Option for Patients

Penn State Health announced a new partnership with Highmark Health, a national, blended health organization based in Pittsburgh, and Contessa, an Amedisys company (NASDAQ: AMED), the nation's leading operator of high-acuity home care based in Nashville. The joint venture will operate Penn State Health Home Recovery Care which includes Hospital Care at Home and Skilled Nursing Care at Home, bringing all the essential elements of hospital and skilled nursing care into the comfort of patients' home

Yahoo | November 10, 2021

Despite Slightly Disappointing Hospice Results, is Amedisys (AMED) Still A Smart Choice?

Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Mid Cap Growth Fund” third quarter 2021 investor letter – a copy of which can be downloaded here. The Russell Midcap® Growth Index (down 0.76%) marginally outperformed its Russell Midcap® Value Index (down 1.01%) counterpart. Individual sectors across the Russell Midcap Growth were largely […]

Yahoo | November 9, 2021

Read More 'AMED' Stories Here

AMED Price Returns

1-mo -21.13%
3-mo -25.40%
6-mo -45.37%
1-year -43.76%
3-year 2.50%
5-year 260.29%
YTD -52.39%
2020 75.73%
2019 42.53%
2018 122.18%
2017 23.65%
2016 8.42%

Continue Researching AMED

Here are a few links from around the web to help you further your research on Amedisys Inc's stock as an investment opportunity:

Amedisys Inc (AMED) Stock Price | Nasdaq
Amedisys Inc (AMED) Stock Quote, History and News - Yahoo Finance
Amedisys Inc (AMED) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8382 seconds.